botulinum toxin type A
botulinum toxin type A: sourced relationships with 1 company · 55 clinical trials tracked · 1 FDA decision.
botulinum toxin type A evidence translation
What we can confirm
1 FDA record · 55 tracked trials
What it means
What to watch
Prepared research question
How could botulinum toxin type A → RVNC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| Revance Therapeutics, Inc. (RVNC) Reported 2022-09-07 · Current development: unknownSource Benign Essential Blepharospasm; Adductor Spasmodic Dysphonia | Phase 4 |
| Revance Therapeutics, Inc. (RVNC) Glabellar Frown Lines | Phase 4 |
| Revance Therapeutics, Inc. (RVNC) Reported 2022-09-07 · Current development: unknownSource Glabellar Frown Lines | Phase 4 |
Clinical Trial Registry Records (55)showing 10 most recent
A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD
Primary endpoint: Motor Alignment Success
A Prospective, Open-label Study to Evaluate Subject Satisfaction and Psychosocial Outcomes After Treatment of Jawline and Neck With BOTOX® Cosmetic and JUVÉDERM® Products
Primary endpoint: Percentage of Participants With Response of Satisfied or Very Satisfied on Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction Follow-Up
Effect of Internal Anal Sphincter Botulinum Toxin A Injection 7 Days Before Hemorrhoidectomy on Postoperative Pain: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Primary endpoint: Postoperative Pain Intensity Within the First 7 Days After Hemorrhoidectomy
Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study
Primary endpoint: Patient Global Improvement
Investigating the Efficacy of Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis Management
Primary endpoint: Synkinesis Assessment Questionnaire (SAQ)
Hyaluronic Acid Versus Botox Injection in Treatment of Life Long Drug Resistant Premature Ejaculation. Which is Better? Randomized Study
Primary endpoint: Change in intravaginal ejaculatory latency time
PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial
Primary endpoint: Primary Fascial Closure (PFC) at conclusion of Hernia Surgery (Yes / No, determined by surgeon)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine
Primary endpoint: Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine
Primary endpoint: Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
Primary endpoint: Degree of pain
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with botulinum toxin type A?
botulinum toxin type A has dated SEC/FDA relationship records for Revance Therapeutics, Inc..
How many clinical trials involve botulinum toxin type A?
BioSniper tracks 55 clinical trials involving botulinum toxin type A.
What is botulinum toxin type A's latest FDA decision?
The most recent tracked FDA decision for botulinum toxin type A is Approval, dated September 7, 2022.